Please try another search
Glycorex Transplantation AB (publ), a medical technology company, engages in the development, production, and sale of products for use in organ transplantation. It develops a molecular level nanosurgical technology that specifically selects and removes antibodies in the blood focusing areas within transplants, blood transfusion, and blood products, as well as autoimmune disease. The company’s principal product is Glycosorb-ABO, which facilitates the transplantation of organs over the blood group barriers that is used for the blood group-incompatible kidney, liver, heart, lungs, pancreatic, and stem cells transplantation procedures. It also offers Glycosorb UBP, a blood donor plasma tool for the treatment of donor blood. It serves in Europe, Austria, France, Germany, the Netherlands, and Spain. Glycorex Transplantation AB (publ) was founded in 1996 and is headquartered in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Johan Laven | 50 | 2022 | CEO & Director |
Tomas Westergren | 60 | 2012 | Deputy Director |
Kurt Nilsson | 71 | 1996 | Director |
Leni von Bonsdorff | 62 | 2021 | Director |
Joakim Jagorstrand | 55 | 2023 | Director |
Bjorn Larsson | 59 | 2023 | Chairman of the Board |
Fredrik Johansson | 36 | 2023 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review